From Mesenchymal Stromal/Stem Cells to Insulin-Producing Cells: Immunological Considerations

Area of Science:

• Immunology
• Regenerative Medicine
• Endocrinology

Background:

• Mesenchymal stem cells (MSCs) offer a potential alternative to insulin injections and pancreatic transplants for type 1 diabetes mellitus (T1DM).
• Conflicting data exists regarding the immunomodulatory profile of MSCs, with some studies reporting immune privilege and others indicating potential immune responses.

Purpose of the Study:

• To critically review the intricate mechanisms of MSC immunomodulation in T1DM.
• To discuss strategies for enhancing MSC therapeutic effects.
• To explore donor selection criteria and future research directions for MSC-based T1DM therapy.

Main Methods:

• Literature review of studies on MSC-based therapy for T1DM.
• Analysis of MSC immunomodulatory mechanisms and influencing factors.
• Evaluation of methods to enhance MSC efficacy and safety.

Main Results:

• MSCs possess immunomodulatory functions, but their effectiveness can be influenced by various factors.
• Strategies like cytokine pretreatment, mTOR inhibitors, Tregs, and gene manipulation may enhance MSC effects.
• Donor selection based on HLA matching, PD-L1 expression, and absence of DSAs is crucial.

Conclusions:

• Optimizing MSC immunomodulation and donor selection are key for successful T1DM therapy.
• Further research, including studies in humanized mice, is necessary to advance clinical applications of MSC-derived insulin-producing cells.